Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Conditions
Head and Neck Cancer - Lung Cancer - Lip Cancer - Lip Neoplasms - Head and Neck Cancers
Conditions: official terms
Head and Neck Neoplasms - Lip Neoplasms - Lung Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Intervention
Name: Tumor biopsy Type: Procedure
Name: Phlebotomy Type: Procedure
Overall Status
Recruiting
Summary
The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
Detailed Description
The endpoints of the study are

1. To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance.

2. To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:Newly diagnosed patients with head and neck cancer who has tumor accessible to tumor oxygenation measurement with a microelectrode.
Location
Stanford University School of Medicine
Stanford, California, United States
Status: Recruiting
Contact: Amanda Simmons - 650-724-4606 - amandals@stanford.edu
Start Date
September 1998
Completion Date
April 2017
Sponsors
Stanford University
Source
Stanford University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page